AREG and neoplasm: When studied in RAS WT mCRC patients treated with EGFR-targeted therapy, high EREG and AREG expression were associated with improved survival regardless of the EGFR-targeted mAb treatment (i.e. cetuximab or panitumumab), combination chemotherapy therapy regimen (i.e. FOLFOX or FOLFIRI), and primary tumor location (i.e. left or right), even when adjusted for other prognostic variables, such as tumor grade and peritoneal metastases among others [64].